FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE
Peakfluorescein sodium and benoxinate hydrochloride
NDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE (fluorescein sodium and benoxinate hydrochloride) by Bausch + Lomb is 12. First approved in 2020.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Fluorescein Sodium and Benoxinate Hydrochloride is a topical ophthalmic anesthetic combination solution used to numb the eye during diagnostic and minor surgical procedures. The benoxinate provides rapid corneal anesthesia within 5-45 seconds, while fluorescein serves as a diagnostic tracer dye. The effect lasts approximately 20 minutes per application, with redosing capability every 10-20 minutes.
Peak11.3 years to LOE
Product is at peak commercial maturity with no active IRA pricing negotiations, suggesting stable but potentially plateauing market dynamics and a consolidated, efficient commercial team.
Mechanism of Action
12.2 Pharmacodynamics Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration. The anesthetic effect may be extended by subsequent administration 10-20 minutes after the last administration.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this Bausch + Lomb ophthalmic product offers career stability in a mature, niche therapeutic area with no competitive pressure and strong patent protection through 2037. Roles will focus on driving market penetration, managing clinical relationships with ophthalmologists, and optimizing commercial operations rather than pioneering new indications.
Brand Manager
Worked on FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.